Mavacamten Treatment Patterns in Obstructive Heart Thickening
Treatments studied
Part of Heart & circulation clinical trials.
This study tracks how mavacamten (a heart medication) works in Japanese patients with obstructive hypertrophic cardiomyopathy—a condition where the heart muscle becomes abnormally thick and blocks blood flow. The trial aims to understand how well the treatment works and how doctors use it in real-world care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with obstructive hypertrophic cardiomyopathy (HCM)—abnormal heart muscle thickening with restricted blood flow, confirmed by heart imaging and measurements
- Heart function measured as 55% or better (normal ejection fraction)
- Currently taking or planning to take mavacamten, or have taken it continuously for at least 16 weeks
- Taking a stable dose of cibenzoline (a heart rhythm medication) for at least 3 months before starting mavacamten
- At least 18 years old
- Not pregnant or planning to become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well mavacamten works in real life for adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is thickened and blocks blood flow. It may help improve symptoms like shortness of breath or chest pain.
This study tests whether mavacamten, a medication that may help the heart use energy better, can improve symptoms in people with obstructive hypertrophic cardiomyopathy. It aims to see if this drug helps with chest pain and shortness of breath, and improve overall heart function.
This study looks at how mavacamten (a heart medication) works for people with obstructive hypertrophic cardiomyopathy (HCM)—a condition where heart muscle becomes too thick. Researchers will review medical records and ask patients about their experiences with the treatment.
This study tracks the safety of Mavacamten in people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle thickens and blocks blood flow). It helps doctors understand how the drug works in everyday use in Japan.
This study looks at adults with a heart condition called obstructive hypertrophic cardiomyopathy. It tracks what happens after they start taking the medicine mavacamten, to learn more about its effects and how it works in real life.
This study tests whether adding the drug mavacamten to a heart procedure (radiofrequency ablation) helps people with a thickened heart muscle that blocks blood flow. It may reduce symptoms like chest pain or shortness of breath.
Hear when a new Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.